To test whether Clec9a-TAP siRNA can also inhibit TAP in TAP sufficient RMA tumor cells, expression of TAP was partially and transiently reduced in the tumor bearing mice by treatment with a TAP siRNA targeted to the RMA tumor cells by conjugation to a nucleolin binding DNA aptamer (Nucl-TAP siRNA) as previously described [13]. The gene discussed is CLEC9A; the disease is neoplasm.